In a clinical trial of more than 3,000 adults with obesity, participants who received the highest dose of orforglipron, 36 milligrams, lost 11.2% of their body weight -- about 25 pounds on average -- over more than 16 months
Current status of glucagon-like Peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: a clinical perspective
By identifying and titrating at the patients pace , we can improve tolerability
Its disheartening to put in the effortmeal prepping, counting calories, hitting the gymand still not see the scale budge
Many individuals find that maintaining consistent hydration alongside fiber intake helps support better digestive comfort over time
However, these medications do not directly target thyroid function or autoimmune processes, which is an important distinction when considering their potential role in Hashimoto's disease management